Kane Biotech (CVE:KNE) Stock Price Up 14.3% – Here’s What Happened

Kane Biotech Inc. (CVE:KNE)’s stock price shot up 14.3% during mid-day trading on Thursday . The stock traded as high as C$0.04 and last traded at C$0.04. 129,500 shares were traded during mid-day trading, an increase of 5% from the average session volume of 123,813 shares. The stock had previously closed at C$0.04.

Kane Biotech Trading Up 14.3%

The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The business’s 50 day simple moving average is C$0.03 and its 200 day simple moving average is C$0.04. The stock has a market cap of C$6.65 million, a P/E ratio of -0.44 and a beta of 0.29.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.